Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

著者: Fred Saad, Noel W. Clarke, Mototsugu Oya, Neal D. Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Niven Mehra, Francis Parnis, Emma Brown, Friederike Schlürmann, Jae Young Joung, Mikio Sugimoto, Oliver Sartor, Yuzhen Liu, Christian Poehlein, Laura Barker, Paula Michelle del Rosario, Andrew J. Armstrong - The Lancet 2023 被引用: 288